1. Home
  2. MATH vs KYNB Comparison

MATH vs KYNB Comparison

Compare MATH & KYNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

MATH

Metalpha Technology Holding Limited

HOLD

Current Price

$0.97

Market Cap

39.7M

Sector

Finance

ML Signal

HOLD

Logo Kyntra Bio Inc. Common Stock

KYNB

Kyntra Bio Inc. Common Stock

N/A

Current Price

$8.55

Market Cap

32.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MATH
KYNB
Founded
2015
1993
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
39.7M
32.8M
IPO Year
2016
2014

Fundamental Metrics

Financial Performance
Metric
MATH
KYNB
Price
$0.97
$8.55
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
25.9K
16.5K
Earning Date
05-29-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
9552.08
EPS
N/A
N/A
Revenue
N/A
$6,440,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$3.10
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.73
$6.32
52 Week High
$4.10
$9.58

Technical Indicators

Market Signals
Indicator
MATH
KYNB
Relative Strength Index (RSI) 49.66 68.12
Support Level $0.81 $6.66
Resistance Level $1.17 $8.99
Average True Range (ATR) 0.09 0.36
MACD 0.01 0.09
Stochastic Oscillator 43.80 86.41

Price Performance

Historical Comparison
MATH
KYNB

About MATH Metalpha Technology Holding Limited

Metalpha Technology Holding Ltd is a digital asset focused wealth management company. The company predominantly generates revenue from the execution of cryptocurrency-related transactions, which includes the issuance of derivative products to over-the-counter (OTC) clients and its proprietary trading activities. It has partnered with a crypto exchange to provide crypto derivative market-making services for its clients, facilitating the trading of crypto derivative products. In addition, the company also engages in providing traditional financial derivative products, and asset management services. It operates in a single segment which is the trading of proprietary digital assets and derivative contracts, and generates majority of its revenue from Hong Kong.

About KYNB Kyntra Bio Inc. Common Stock

Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.

Share on Social Networks: